会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • NOVEL POLYMERS
    • 新型聚合物
    • WO2010131032A2
    • 2010-11-18
    • PCT/GB2010/050769
    • 2010-05-11
    • PHARMAPATENTS GLOBAL LTDMCCORMACK, Keith
    • MCCORMACK, Keith
    • A61K47/48
    • A61K31/795A61K47/55A61K47/59C08G75/00C08G75/04
    • The present invention relates to polymers comprising monomer units derived from captopril, and their use in the treatment or prevention of collagen deposition, fibrosis, scars, burns, or unwanted tissue formation. The present invention further relates to processes for the preparation of said polymers and to pharmaceutical compositions and medical products comprising the polymers. Also encompassed by the present invention are polymers comprising monomer units derived from other ACE inhibitors such as zofenopril, alacepril, rentiapril or pivalopril, or from vasopeptidase inhibitors such as fasidotrilat, omapatrilat or ilepatril.
    • 本发明涉及包含衍生自卡托普利的单体单元的聚合物及其在治疗或预防胶原沉积,纤维化,瘢痕,烧伤或不想要的组织形成中的用途。 本发明还涉及制备所述聚合物的方法以及包含聚合物的药物组合物和医药产品。 本发明还包括包含衍生自其他ACE抑制剂如佐芬普利,阿拉普利,利莫普利或新戊酰胺的单体单元,或来自血管肽酶抑制剂如法西多瑞拉,奥沙曲坦或依他帕替的聚合物。
    • 3. 发明申请
    • BINARY COMPOSITIONS COMPRISING AN NO-DONOR AND AN A-SMASE INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES
    • 包含免疫抑制剂和用于治疗呼吸道疾病的A-SMASE抑制剂的二元组合物
    • WO2010035047A1
    • 2010-04-01
    • PCT/GB2009/051262
    • 2009-09-25
    • PHARMAPATENTS GLOBAL LTD.MCCORMACK, Keith
    • MCCORMACK, Keith
    • A61K31/55A61K31/198
    • A61K31/198A61K31/55A61K2300/00
    • The present invention relates to a pharmaceutical composition comprising an A-SMase inhibitor and/or a NO-donor. Preferred A-SMase inhibitors are tricyclic antidepressants, most preferably amitriptyline. A preferred NO-donor is arginine. Preferably the pharmaceutical composition comprises an A-SMase inhibitor and a NO-donor, which preferably act synergistically to inhibit A-SMase. The pharmaceutical composition is suitable for treating or preventing respiratory disorders such as chronic cough, cystic fibrosis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and emphysema. Preferably the pharmaceutical composition is administered by inhalation. The present invention also relates to methods of treating or preventing respiratory disorders, methods of inhibiting A-SMase, and assays for investigating the effect of test compounds upon A-SMase activity in vitro.
    • 本发明涉及包含A-SMase抑制剂和/或NO供体的药物组合物。 优选的A-SMase抑制剂是三环抗抑郁药,最优选阿米替林。 优选的NO供体是精氨酸。 优选地,药物组合物包含A-SMase抑制剂和NO供体,其优选协同作用以抑制A-SMase。 该药物组合物适用于治疗或预防呼吸系统疾病,如慢性咳嗽,囊性纤维化,慢性阻塞性肺病,特发性肺纤维化和肺气肿。 优选地,药物组合物通过吸入给药。 本发明还涉及治疗或预防呼吸系统疾病的方法,抑制A-SMase的方法,以及用于研究试验化合物对体外A-SMase活性的影响的测定方法。